Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishHigh impact
Esc

Kodiak Sciences Stock Jumps 178% on DAYBREAK Phase 3 Data

SEC EDGAR / Kodiak Sciences2 min read6 sources

Why is Kodiak Sciences stock up today?

Kodiak Sciences (KOD) stock jumped 178% to $89.92 on Monday after both Zenkuda and KSI-501 cleared their primary endpoints in the pivotal DAYBREAK Phase 3 wet AMD trial.

Key numbers

KOD 1-Day Gain+178%from $32.35 close on Sept 25 to $89.92
Zenkuda Primary Endpoint p-Valuep=0.0007well below the 0.05 significance threshold; non-inferior to Eylea at year one
Patients on 6-Month Dosing (Zenkuda)54%vs. monthly injections required for comparator Eylea
KSI-501 Vision Endpoint p-Valuep=0.0036second drug also cleared its primary target in wet AMD
Short Interest at Time of Release17% of float10.67M shares short; 18.4 days to cover — amplified the squeeze
KOD Post-Surge Market Cap$5.64B+$3.6B added in one session vs. ~$2.0B pre-announcement

What happened

Kodiak Sciences (KOD) stock jumped 178% to $89.92 on Monday after both Zenkuda and KSI-501 cleared their primary endpoints in the pivotal DAYBREAK Phase 3 wet AMD trial. Zenkuda, an anti-VEGF eye treatment designed to be given just once every six months, matched the year-one vision gains of Eylea — the world's most-prescribed AMD medicine — with a p-value of 0.0007, a result so strong it is extremely unlikely to be due to chance alone. KSI-501, a dual-target drug that blocks two disease-driving proteins at once, also hit its vision endpoint with a p-value of 0.0036. Kodiak plans to file for U.S. approval in Q4 2026, supported by five positive Phase 3 studies spanning wet AMD, diabetic retinopathy and retinal vein occlusion.

Why it matters

Kodiak Sciences' DAYBREAK result matters because wet AMD — a condition that destroys central vision and affects an estimated 10–20 million people worldwide — has long required monthly eye injections for most patients. Zenkuda's ability to keep 54% of patients on a six-month dosing schedule would cut clinic visits sharply if the drug wins approval, which Kodiak says could come as early as Q4 2026. The win also triggered a short squeeze: 17% of KOD's tradable float had been borrowed and sold short, and those traders were forced to buy back shares in a hurry once the data hit, amplifying the already dramatic move.

Who this affects

Marketbullish
High impact
Small-cap biotech stocks jumped broadly on the ophthalmology sector validation.
Companybullish
High impact
KOD shareholders gained roughly $3.6B in market value in a single session.
Competitorsbearish
Medium impact
Regeneron fell 4.5% and EyePoint fell 8.6% as Kodiak's AMD data raised competitive pressure.
Industrybullish
Medium impact
Long-acting AMD treatments gained clinical proof; focus shifts to Kodiak's FDA filing timeline.

Kodiak Sciences vs Regeneron, EyePoint Pharmaceuticals

Kodiak SciencesKOD$5.64B+178%—17%
RegeneronREGN$75.12B-4.54%13x—
EyePoint PharmaceuticalsEYPT$285M-8.56%——

As of 2026-09-28

How we got here

  1. Kodiak Q2 results: cash $125.9M; DAYBREAK topline confirmed for Sept 28

  2. KOD stock rose ~7% as anticipation for DAYBREAK topline data built

  3. DAYBREAK topline released 8:30 AM ET; both Zenkuda and KSI-501 cleared primary endpoints

  4. Heavy short sellers forced to cover 10.67M shares; 18.4 days-to-cover squeeze

  5. Kodiak plans BLA submission for Zenkuda backed by five Phase 3 studies

What to watch

  • Kodiak BLA submission to FDA for Zenkuda spanning five positive Phase 3 studiesQ4 2026
  • KSI-101 PEAK Phase 3 topline data in macular edema from inflammation2026-12-31
  • AAO annual meeting: first physician reaction to DAYBREAK data post-announcementOctober 2026

Educational content only. Not investment advice.

More briefsAll briefs →